Sign up to save your podcasts
Or
Share On the Horizon: Achieving Durable VEGF Suppression in nAMD and DME
Share to email
Share to Facebook
Share to X
Share to email
Share to Facebook
Share to X
Or
On the Horizon: Achieving Durable VEGF Suppression in nAMD and DME
CME credits: 0.50
Valid until: 30-07-2022
Claim your CME credit at https://reachmd.com/programs/cme/horizon-achieving-durable-vegf-suppression-namd-and-dme/12662/
One of the biggest challenges with anti-VEGF therapy is the burden of continued and frequent treatment. Fortunately, new options are on the horizon in neovascular age-related macular degeneration (nAMD) and diabetic macular edema (DME) that can safely reduce treatment burden while improving vision. So what are these strategies, and what is the latest evidence for their use?
Join us as leading experts, Diana Do, Nancy Holekamp, and Carl Regillo, discuss several new strategies to improve VEGF suppression in nAMD and DME. Hear about unique mechanisms of action, the most recent clinical evidence supporting the use of these developments, and their potential applications in clinical practice.
View all episodes
By ReachMD
4.3
33 ratings
CME credits: 0.50
Valid until: 30-07-2022
Claim your CME credit at https://reachmd.com/programs/cme/horizon-achieving-durable-vegf-suppression-namd-and-dme/12662/
One of the biggest challenges with anti-VEGF therapy is the burden of continued and frequent treatment. Fortunately, new options are on the horizon in neovascular age-related macular degeneration (nAMD) and diabetic macular edema (DME) that can safely reduce treatment burden while improving vision. So what are these strategies, and what is the latest evidence for their use?
Join us as leading experts, Diana Do, Nancy Holekamp, and Carl Regillo, discuss several new strategies to improve VEGF suppression in nAMD and DME. Hear about unique mechanisms of action, the most recent clinical evidence supporting the use of these developments, and their potential applications in clinical practice.